FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2122843800> ?p ?o ?g. }

• W2122843800 endingPage "249" @default.
• W2122843800 startingPage "241" @default.
• W2122843800 abstract "<h2>Summary</h2><h3>Background</h3> Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors. <h3>Methods</h3> Two neuroradiologists independently reviewed 2572 fluid-attenuated inversion recovery (FLAIR) MRI scans from 262 participants in two phase 2 studies of bapineuzumab and an open-label extension study. Readers were masked to the patient's treatment, <i>APOE</i> ɛ4 genotype, medical history, and demographics. Patients were included in risk analyses if they had no evidence of ARIA-E in their pre-treatment MRI, had received bapineuzumab, and had at least one MRI scan after treatment. We used Kaplan-Meier survival analysis to examine the distribution of incident ARIA-E from the start of bapineuzumab treatment and proportional hazards regression models to assess risk factors associated with ARIA. <h3>Findings</h3> 210 patients were included in the risk analyses. 36 patients (17%) developed ARIA-E during treatment with bapineuzumab; 15 of these ARIA-E cases (42%) had not been detected previously. 28 of these patients (78%) did not report associated symptoms. Adverse events, reported in eight symptomatic patients, included headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 of the patients with ARIA-E (47%), compared with seven of 177 (4%) patients without ARIA-E. 13 of the 15 patients in whom ARIA were detected in our study received additional treatment infusions while ARIA-E were present, without any associated symptoms. Occurrence of ARIA-E increased with bapineuzumab dose (hazard ratio [HR] 2·24 per 1 mg/kg increase in dose, 95% CI 1·40–3·62; p=0·0008) and presence of <i>APOE ɛ4</i> alleles (HR 2·55 per allele, 95% CI 1·57–4·12; p=0·0001). <h3>Interpretation</h3> ARIA consist of a spectrum of imaging findings with variable clinical correlates, and some patients with ARIA-E remain asymptomatic even if treatment is continued. The increased risk of ARIA among <i>APOE ɛ4</i> carriers, its association with high bapineuzumab dose, and its timecourse in relation to dosing suggest an association between ARIA and alterations in vascular amyloid burden. <h3>Funding</h3> Elan Corporation, Janssen Alzheimer Immunotherapy, Wyeth Pharmaceuticals, and Pfizer." @default.
• W2122843800 created "2016-06-24" @default.
• W2122843800 creator A5001795846 @default.
• W2122843800 creator A5002183686 @default.
• W2122843800 creator A5003680013 @default.
• W2122843800 creator A5009252002 @default.
• W2122843800 creator A5013924216 @default.
• W2122843800 creator A5014646926 @default.
• W2122843800 creator A5018836358 @default.
• W2122843800 creator A5021821559 @default.
• W2122843800 creator A5025513316 @default.
• W2122843800 creator A5026400639 @default.
• W2122843800 creator A5033585095 @default.
• W2122843800 creator A5043107463 @default.
• W2122843800 creator A5045336469 @default.
• W2122843800 creator A5049016177 @default.
• W2122843800 creator A5058984019 @default.
• W2122843800 creator A5059216826 @default.
• W2122843800 creator A5063444335 @default.
• W2122843800 creator A5076264560 @default.
• W2122843800 creator A5080281958 @default.
• W2122843800 creator A5088718520 @default.
• W2122843800 date "2012-03-01" @default.
• W2122843800 modified "2023-10-11" @default.
• W2122843800 title "Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis" @default.
• W2122843800 cites W1575894848 @default.
• W2122843800 cites W1968954730 @default.
• W2122843800 cites W1978873309 @default.
• W2122843800 cites W1978924496 @default.
• W2122843800 cites W1989255369 @default.
• W2122843800 cites W1998616945 @default.
• W2122843800 cites W2042282383 @default.
• W2122843800 cites W2054802037 @default.
• W2122843800 cites W2068394373 @default.
• W2122843800 cites W2069315029 @default.
• W2122843800 cites W2071758656 @default.
• W2122843800 cites W2077023014 @default.
• W2122843800 cites W2086572083 @default.
• W2122843800 cites W2088018375 @default.
• W2122843800 cites W2096898082 @default.
• W2122843800 cites W2108216694 @default.
• W2122843800 cites W2113770731 @default.
• W2122843800 cites W2124210220 @default.
• W2122843800 cites W2131943911 @default.
• W2122843800 cites W2143060791 @default.
• W2122843800 cites W2143238511 @default.
• W2122843800 cites W2146653387 @default.
• W2122843800 cites W2148034536 @default.
• W2122843800 cites W2150231759 @default.
• W2122843800 cites W2151343738 @default.
• W2122843800 cites W2164300497 @default.
• W2122843800 doi "https://doi.org/10.1016/s1474-4422(12)70015-7" @default.
• W2122843800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4063417" @default.
• W2122843800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22305802" @default.
• W2122843800 hasPublicationYear "2012" @default.
• W2122843800 type Work @default.
• W2122843800 sameAs 2122843800 @default.
• W2122843800 citedByCount "368" @default.
• W2122843800 countsByYear W21228438002012 @default.
• W2122843800 countsByYear W21228438002013 @default.
• W2122843800 countsByYear W21228438002014 @default.
• W2122843800 countsByYear W21228438002015 @default.
• W2122843800 countsByYear W21228438002016 @default.
• W2122843800 countsByYear W21228438002017 @default.
• W2122843800 countsByYear W21228438002018 @default.
• W2122843800 countsByYear W21228438002019 @default.
• W2122843800 countsByYear W21228438002020 @default.
• W2122843800 countsByYear W21228438002021 @default.
• W2122843800 countsByYear W21228438002022 @default.
• W2122843800 countsByYear W21228438002023 @default.
• W2122843800 crossrefType "journal-article" @default.
• W2122843800 hasAuthorship W2122843800A5001795846 @default.
• W2122843800 hasAuthorship W2122843800A5002183686 @default.
• W2122843800 hasAuthorship W2122843800A5003680013 @default.
• W2122843800 hasAuthorship W2122843800A5009252002 @default.
• W2122843800 hasAuthorship W2122843800A5013924216 @default.
• W2122843800 hasAuthorship W2122843800A5014646926 @default.
• W2122843800 hasAuthorship W2122843800A5018836358 @default.
• W2122843800 hasAuthorship W2122843800A5021821559 @default.
• W2122843800 hasAuthorship W2122843800A5025513316 @default.
• W2122843800 hasAuthorship W2122843800A5026400639 @default.
• W2122843800 hasAuthorship W2122843800A5033585095 @default.
• W2122843800 hasAuthorship W2122843800A5043107463 @default.
• W2122843800 hasAuthorship W2122843800A5045336469 @default.
• W2122843800 hasAuthorship W2122843800A5049016177 @default.
• W2122843800 hasAuthorship W2122843800A5058984019 @default.
• W2122843800 hasAuthorship W2122843800A5059216826 @default.
• W2122843800 hasAuthorship W2122843800A5063444335 @default.
• W2122843800 hasAuthorship W2122843800A5076264560 @default.
• W2122843800 hasAuthorship W2122843800A5080281958 @default.
• W2122843800 hasAuthorship W2122843800A5088718520 @default.
• W2122843800 hasBestOaLocation W21228438002 @default.
• W2122843800 hasConcept C101070640 @default.
• W2122843800 hasConcept C120665830 @default.
• W2122843800 hasConcept C121332964 @default.
• W2122843800 hasConcept C126322002 @default.
• W2122843800 hasConcept C126838900 @default.
• W2122843800 hasConcept C142724271 @default.

• next